IL33 and airway hyperresponsiveness: We did this by stimulating airway fibroblasts with a 1 ng/ml dose of recombinant IL-1α, IL-1β or IL-33 for 24 hours and then assessed the release of inflammatory mediators known to be involved in chronic inflammation, and airway hyperresponsiveness in asthma7,21.